SIM
BCRX icon

Strategic Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Strategic Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,336
Closed -$116K – 109
2015
Q4 		$116K Buy
+11,336
New +$113K 0.07% 98
2014
Q3 		– Sell
-20,000
Closed -$255K – 105
2014
Q2 		$255K Buy
+20,000
New +$195K 0.06% 58

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Strategic Investment Management's BCRX Position: Q1 2016 in Review

Strategic Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 11,336 shares — an estimated $116K sold.

Strategic Investment Management first reported a position in BCRX in Q2 2014 and held it in 2 quarters. The position peaked at $255K in Q2 2014. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

  • Strategic Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Strategic Investment Management sold 11,336 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $116K.
  • Strategic Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Strategic Investment Management's BioCryst Pharmaceuticals position peaked at $255K in Q2 2014.
  • 109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Strategic Investment Management's 13F filing for Q1 2016, filed 16 May 2016.